<DOC>
	<DOCNO>NCT01564017</DOCNO>
	<brief_summary>As part registration plan product perform Phase I study present trial design compare efficacy 5 different dos subcutaneous immunotherapy depot presentation .</brief_summary>
	<brief_title>Dose-response Study With Subcutaneous Immunotherapy Standardized Dermatophagoides Pteronyssinus ( DPT ) Extract</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>1 . Patients must sign Informed Consent Form . 2 . Patients must 18 60 year age . 3 . Patients perennial allergic rhinoconjunctivitis produce Dermatophagoides pteronyssinus least 2 year prior participate study . Although pathology study allergic rhinoconjunctivitis , patient concomitant mild moderate asthma may include . 4 . Patients skin prick test result great equal 3 mm diameter Dermatophagoides pteronyssinus . 5 . Patients specific Immunoglobulin E ( IgE ) great equal class 2 ( CAP/PHADIA ) Dermatophagoides pteronyssinus . 6 . Patients preferably monosensitized Dermatophagoides pteronyssinus . Polysensitized patient may include study sensitization produce : Pollens whose season period overlap study treatment , overlap , whose specific IgE level less class 2 . Perennial allergen specific IgE level less class 2 . Allergens cohabit patient whose environmental level high enough produce symptom study period . 7 . Women childbearing potential must negative urine pregnancy test time begin study . 8 . Furthermore , woman childbearing potential must agree use adequate contraceptive method study sexually active . 1 . Patients stable continue use medication treat allergic condition 2 week prior inclusion study . 2 . Patients sensitize specific IgE level great equal class 2 perennial seasonal allergen clinically relevant include mite unless cross reactive Dermatophagoides pteronyssinus . 3 . Patients receive immunotherapy 5 year prior study either allergen test allergen crossreactive , currently receive immunotherapy allergen . 4 . Patients severe asthma FEV1 &lt; 70 % asthma require treatment inhaled systemic corticoid time study 8 week immediately prior onset treatment . 5 . Patients immunological , cardiac , renal hepatic disease illness investigator deem may interfere study . 6 . Patients prior history anaphylaxis . 7 . Patients chronic urticaria . 8 . Patients moderatesevere atopic dermatitis . 9 . Patients clinically relevant malformation upper respiratory tract . 10 . Patients participate another clinical trial within 3 month prior study . 11 . Patients treat tricyclic antidepressant , psychotropic drug , betablockers , angiotensinconverting enzyme inhibitor ( ACEIs ) . 12 . Women pregnant breastfeed childbearing age agree use adequate contraception sexually active demonstrate surgically sterilize mean bear child . 13 . Patients attend study visit . 14 . Patients uncooperative refuse participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Allergic rhinoconjunctivitis</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>D. pteronyssinus</keyword>
	<keyword>house dust allergy</keyword>
</DOC>